With the return of Europe’s leading broadcast event just weeks away, JW Player (JWP) has announced it will be unveiling a new end-to-end solution at IBC, one th.
Flowbird today announces the acquisition of YourParkingSpace – the UK’s leading pre-book and subscription marketplace trusted by over 5m drivers.
Flowbird is a leading global provider of software, mobile apps, payments and hardware solutions .
Manchester Airports Group (MAG) has announced the merger of its American and digital divisions – MAGO and MAG USA – to form a new business, CAVU.
The newly-formed business aims to help clients worldwide develop better customer experiences .
High dose rate (HDR) brachytherapy is a form of close range radiotherapy whereby dose is delivered by means of an internal radiation source. By doing so, a high level of dose con-formity and accuracy can be achieved. However, due to the high source activity coupled with the close proximity of radio-sensitive organs such as the rectum, bladder and urethra, there exists the potential of incorrect dose delivery; the irradiation of these organs may con-sequently lead to post-treatment complications. As a result, the need for accurate forms of quality assurance methodology which can verify different aspects of the treatment delivery is paramount. These methodologies must be able to perform real-time dose analysis to monitor crucial organ exposure as well as accurately localise the HDR source within space to verify its position according to the treatment plan.
An End-to-end Phantom was developed with anatomically correct Gel Prostate phantoms to create an anthropomorphic representation of t
Dr. Feng Ren, Chief Scientific Officer (CSO) and head of global research and development is named co-CEO of Insilico Medicine Highlights: Insilico Medicine is a global, end-to-end, fully-integrated AI-powered biotechnology company with three business models: AI platform, collaboration, and internal pipeline. It utilizes AI and a fully distributed, highly parallel discovery model to rapidly develop its own drugs. Since 2021, the company has nominated 8 preclinical candidates and reached Phase I clinical trials with an AI-discovered and AI-designed molecule. It is also developing a set of AI platforms for target discovery, multi-parameter optimization, generative chemistry, and prediction of clinical trials. In the pharmaceutical industry, the internal pipeline, and especially, clinical assets, are much more important and expensive than computational platforms and other enabling technologies. Historically, companies in computationally-augmented discovery, reduced or completely eliminated